News | April 04, 2025
Lupin acquires UK-based Renascience Pharma for £12.3 million
The portfolio includes branded injectable cephalosporines for infectious diseases
The portfolio includes branded injectable cephalosporines for infectious diseases
The IND application supports the next phase of development of SBO-154
Approval based on AEGEAN Phase III trial results which showed a 32% reduction in the risk of recurrence, progression or death vs. neoadjuvant chemotherapy alone
Approval brings AstraZeneca and Daiichi Sankyo’s Enhertu earlier in the treatment of HR-positive, HER2-low breast cancer and broadens the eligible patient population to those with HER2-ultralow disease
PRX-PLUS has a unique product feature with its deep-impacting formula
Sensory Boxes include items such as drawing boards and fidget balls to support management of anxiety and improve shopping experience
EC decision marks the fourth approval for CAPVAXIVE for pneumococcal vaccination in adults
The first-of-its-kind study will evaluate potential association between GSK’s shingles vaccine and reduced dementia risk, building on growing body of evidence from observational and retrospective studies
Collaboration combines data, identity capture and Web 3.0 crypto technologies to enhance product safety, traceability, and data integrity for AI systems
The freshly infused capital will primarily be deployed towards expansion and research & development
Subscribe To Our Newsletter & Stay Updated
